重新审视美墨加协议对公共卫生的影响。
Revisiting the public health implications of the United States-Mexico- Canada agreement.
机构信息
School of Law, City University of Hong Kong, Hong Kong, Hong Kong SAR.
出版信息
Global Health. 2020 Jun 5;16(1):50. doi: 10.1186/s12992-020-00579-y.
Abstract
This commentary re-examines a recent article by Labonté et al on the recent changes to two relevant provisions relating to patent rights in the final version of the United-States-Mexico-Canada Agreement (USMCA). Although the USMCA's final revised version does not add more pharmaceutical patent protection than those that already exist in the three trading partners, the agreement has done little to enhance access to generic medicines and biosimilars.
摘要
本评论重新审视了 LaBonté 等人最近一篇关于《美国-墨西哥-加拿大协定》（USMCA）最终版本中与专利权利相关的两项规定最近变化的文章。尽管 USMCA 的最终修订版并没有比三个贸易伙伴现有的专利保护增加更多的药品专利保护，但该协议在增加仿制药和生物类似药的可及性方面几乎没有起到任何作用。
相似文献
1
Revisiting the public health implications of the United States-Mexico- Canada agreement.重新审视美墨加协议对公共卫生的影响。
Global Health. 2020 Jun 5;16(1):50. doi: 10.1186/s12992-020-00579-y.
2
USMCA (NAFTA 2.0): tightening the constraints on the right to regulate for public health.美墨加协定（北美自由贸易协定 2.0）：收紧对监管公共健康的权利的限制。
Global Health. 2019 May 14;15(1):35. doi: 10.1186/s12992-019-0476-8.
3
Intellectual property and access to medicines: mapping public attitudes toward pharmaceuticals during the United States-Mexico-Canada Agreement (USMCA) negotiation process.知识产权与药品获取：美国-墨西哥-加拿大协定（USMCA）谈判期间公众对药品的态度分析。
Global Health. 2021 Aug 20;17(1):92. doi: 10.1186/s12992-021-00740-1.
4
Analyzing the impact of trade and investment agreements on pharmaceutical policy: provisions, pathways and potential impacts.分析贸易和投资协定对药品政策的影响：规定、途径和潜在影响。
Global Health. 2019 Nov 28;15(Suppl 1):78. doi: 10.1186/s12992-019-0518-2.
5
Moderating the impact of patent linkage on access to medicines: lessons from variations in South Korea, Australia, Canada, and the United States.调节专利链接对药品可及性的影响：来自韩国、澳大利亚、加拿大和美国差异的经验教训。
Global Health. 2018 Oct 24;14(1):101. doi: 10.1186/s12992-018-0423-0.
6
USMCA 2.0: a few improvements but far from a 'healthy' trade treaty.美墨加协定 2.0：略有改进，但远非“健康”的贸易协定。
Global Health. 2020 May 6;16(1):43. doi: 10.1186/s12992-020-00565-4.
7
Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health?《与贸易有关的知识产权协定》（TRIPS协定）在拉丁美洲和加勒比地区的实施是否产生了有利于公共卫生的知识产权立法？
Bull World Health Organ. 2004 Nov;82(11):815-21. Epub 2004 Dec 14.
8
[Evolution of the international intellectual property rights system: patent protection for the pharmaceutical industry and access to medicines].[国际知识产权体系的演变：制药行业的专利保护与药品可及性]
Cad Saude Publica. 2007 Feb;23(2):257-67. doi: 10.1590/s0102-311x2007000200002.
9
Just Say No to the TPP: A Democratic Setback for American and Asian Public Health Comment on "The Trans-Pacific Partnership: Is It Everything We Feared for Health?".对 TPP 说不：美国和亚洲公共卫生的民主挫折 评“跨太平洋伙伴关系协定：是否如我们担心的那样对健康不利？”
Int J Health Policy Manag. 2017 Jul 1;6(7):419-421. doi: 10.15171/ijhpm.2016.145.
10
Public health-oriented intellectual property and trade policies in Africa and the regional mechanism under Trade-Related Aspects of Intellectual Property Rights amendment.非洲以公共卫生为导向的知识产权和贸易政策与《与贸易有关的知识产权协定》修订版下的区域机制
Public Health. 2019 Aug;173:1-4. doi: 10.1016/j.puhe.2019.04.019. Epub 2019 Jun 13.
引用本文的文献
1
Fuzzy cooperative game analysis within the international railway freight coalition framework.国际铁路货运联盟框架内的模糊合作博弈分析
Sci Rep. 2025 Jul 1;15(1):20908. doi: 10.1038/s41598-025-05977-z.
本文引用的文献
1
USMCA (NAFTA 2.0): tightening the constraints on the right to regulate for public health.美墨加协定（北美自由贸易协定 2.0）：收紧对监管公共健康的权利的限制。
Global Health. 2019 May 14;15(1):35. doi: 10.1186/s12992-019-0476-8.
2
A Systematic Review of the Cost-Effectiveness of Biologics for Ulcerative Colitis.生物制剂治疗溃疡性结肠炎的成本效益的系统评价
Pharmacoeconomics. 2018 Apr;36(4):419-434. doi: 10.1007/s40273-017-0601-6.
Zotero 插件